# LTL Management

Type: Company

Source: GetYourBrief — https://getyourbrief.com/entity/ltl-management
Canonical HTML page: https://getyourbrief.com/entity/ltl-management

## Timeline

- **2026-07-27**: $5.5B Settlement Announced — J&J proposes a global settlement to resolve around 76,000 pending ovarian cancer talc lawsuits, contingent on 95% claimant approval.
- **2023-01**: Bankruptcy Dismissal — Courts dismiss the LTL Management bankruptcy, ruling it was not filed in good faith, sending talc cases back to trial courts.
- **2021-10**: LTL Management Files for Bankruptcy — J&J employs the 'Texas two-step' strategy, shifting talc liabilities to subsidiary LTL Management, which files for Chapter 11.
- **2020**: J&J Stops Talc Baby Powder Sales in the U.S. — Facing mounting lawsuits, J&J discontinues talc-based baby powder in the U.S. and switches to a cornstarch-based product.

## Recent coverage (3 stories, network-wide)

### J&J's $5.5B Talc Settlement: A Litigation Endgame with 95% Approval Hurdle
2026-07-28 14:40:10 · Sector: legal · Sentiment: Negative · Impact: 7/10 · Sources: 3

The $5.5B proposal to resolve 76,000 ovarian cancer talc lawsuits represents a strategic retreat for J&J, contingent on 95% claimant approval and following failed bankruptcy attempts.
Full story: https://getlegalbrief.com/story/jnj-5-5b-talc-settlement-legal-analysis

### J&J's $5.5B Talc Payout: Ovarian Cancer Claims and Consumer Safety Shift
2026-07-28 14:40:04 · Sector: health · Sentiment: Negative · Impact: 7/10 · Sources: 3

The settlement highlights decades of health concerns over talc's link to ovarian cancer, prompting J&J to switch to cornstarch and underscoring ongoing consumer trust issues.
Full story: https://gethealthbrief.com/story/jnj-talc-cancer-settlement-health-impact

### J&J Clears $5.5B Talc Overhang: Refocusing on $85B Pharma Pipeline
2026-07-28 14:39:57 · Sector: bio · Sentiment: Negative · Impact: 7/10 · Sources: 3

The settlement removes a major litigation distraction, allowing Johnson & Johnson to redirect resources toward its core pharmaceutical and medtech segments, which generate $85B in annual revenue.
Full story: https://getbiobrief.com/story/jnj-talc-settlement-pharma-outlook

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.